Ensign Peak Advisors’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $21.5M | Sell |
170,783
-23,961
| -12% | -$3.01M | 0.04% | 303 |
|
|
2025
Q1 | $21.5M | Buy |
194,744
+21,050
| +12% | +$2.33M | 0.04% | 290 |
|
|
2024
Q4 | $23.7M | Sell |
173,694
-1,141
| -0.7% | -$156K | 0.04% | 290 |
|
|
2024
Q3 | $20.1M | Sell |
174,835
-97,778
| -36% | -$11.3M | 0.04% | 328 |
|
|
2024
Q2 | $37.5M | Buy |
272,613
+117,902
| +76% | +$16.2M | 0.07% | 207 |
|
|
2024
Q1 | $21.3M | Buy |
154,711
+82,103
| +113% | +$11.3M | 0.04% | 314 |
|
|
2023
Q4 | $9.57M | Sell |
72,608
-12,613
| -15% | -$1.66M | 0.02% | 451 |
|
|
2023
Q3 | $9.59M | Sell |
85,221
-10,632
| -11% | -$1.2M | 0.02% | 404 |
|
|
2023
Q2 | $9.04M | Buy |
95,853
+27,433
| +40% | +$2.59M | 0.02% | 442 |
|
|
2023
Q1 | $6.93M | Buy |
68,420
+16,115
| +31% | +$1.63M | 0.02% | 486 |
|
|
2022
Q4 | $6.25M | Buy |
52,305
+7,866
| +18% | +$940K | 0.01% | 508 |
|
|
2022
Q3 | $4.72M | Sell |
44,439
-17,036
| -28% | -$1.81M | 0.01% | 535 |
|
|
2022
Q2 | $5.99M | Sell |
61,475
-4,515
| -7% | -$440K | 0.01% | 490 |
|
|
2022
Q1 | $6.19M | Sell |
65,990
-5,862
| -8% | -$550K | 0.01% | 527 |
|
|
2021
Q4 | $6.12M | Sell |
71,852
-35,105
| -33% | -$2.99M | 0.01% | 606 |
|
|
2021
Q3 | $10.3M | Sell |
106,957
-2,322
| -2% | -$223K | 0.02% | 425 |
|
|
2021
Q2 | $10.6M | Buy |
109,279
+60,600
| +124% | +$5.9M | 0.02% | 417 |
|
|
2021
Q1 | $4.74M | Sell |
48,679
-125,879
| -72% | -$12.2M | 0.01% | 644 |
|
|
2020
Q4 | $16.7M | Sell |
174,558
-33,501
| -16% | -$3.21M | 0.04% | 344 |
|
|
2020
Q3 | $20M | Buy |
208,059
+76,370
| +58% | +$7.34M | 0.05% | 304 |
|
|
2020
Q2 | $16.1M | Buy |
131,689
+38,789
| +42% | +$4.73M | 0.04% | 336 |
|
|
2020
Q1 | $8.04M | Sell |
92,900
-17,948
| -16% | -$1.55M | 0.03% | 398 |
|
|
2019
Q4 | $11.9M | Buy |
+110,848
| New | +$11.9M | 0.03% | 391 |
|